Colorectal cancer remains one of the most frequently diagnosed cancers in the developed world. The advent of new therapeutic agents has further expanded our treatment options. Epidermal growth factor receptor (EGFR) inhibitors have been shown to improve survival in metastatic cancer. However, there remain a substantial proportion of patients who do not benefit from this treatment. KRAS mutation status has been validated to predict the response to EGFR inhibitors with mutant status predicting non-responders. The validation of other predictive and prognostic markers will result in further optimization of the care plan for patient with colorectal cancer; maximising benefits while minimising toxicities. This article aims to provide an update of the various molecular markers for use in detection, prognostication and predicting responses in colon cancer.
INtrODUCtION
Colorectal cancer is the most common cancer diagnosed in Singapore (7277 cases in 2003 -2007) . It accounts for 17.8% of cancers in men and 14.5% in women 1 . The American Cancer Society estimated 142,570 new cases and 51,370 deaths for colorectal cancer in 2010. The mortality rate has declined over the past two decades mainly due to declining incidence rates and improvements in early detection and treatment 2 . The 5 year survival rate for localized stage is 91%; however, this drops to 11% with spread to distant organs.
Surgery remains a principal treatment modality for earlier stage colorectal cancer. Chemotherapeutic options for colorectal cancer have in recent years expanded to include various combinations of 5 fluorouracil, oxaliplatin, irinotecan, epidermal growth factor receptor (EGFR) inhibitors (cetuximab, panitumumab), anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab). The traditional approach to risk stratification and treatment planning was to examine clinicopathologic prognostic markers like stage, number of locally involved lymph nodes, lymphovascular invasion, bowel wall perforation and obstruction. With the advent of multiple biological therapeutic options, coupled with large scale molecular and genomic mapping of colorectal cancer, the landscape of therapeutic approach to colorectal cancer has evolved towards increased use of molecular markers to further individualize treatment plans.
This review intends to provide an update of the various molecular markers for use in detection, prognostication and predicting responses in colon cancer.
EGFr INhIBItOrs rEspONsE mArkErs
A significant advance in the treatment of metastatic colorectal cancer has been the use of targeted drugs (anti-EGFR and anti-VEGF agents). Cetuximab and panitumumab are two EGFR inhibitors with described efficacy in metastatic colorectal cancer. The NCIC CO.17 Canadian trial 3 described benefits of cetuximab monotherapy versus best supportive care in patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan, with prolongation of median survival (4.6 vs 6.1 Proceedings of Singapore Healthcare  Volume 20  Number 1  2011 months, p=0.005). Similar small effects in terms of progression free survival (PFS) with panitumumab was reported in a similar population (7.3 v 8 weeks, p<0.001) 4 . The BOND 5 trial enrolled patients previously treated with irinotecan to cetuximab monotherapy vs cetuximab plus irinotecan arm and reported prolonged time to progression (TTP) (1.5 vs 4.1 months, p<0.001) in the combination arm. No correlation between response rate and EGFR expression by immunohistochemistry was reported in this trial. Subsequently, the CRYSTAL trial 6 reported PFS benefits (8.0 v 8.9 months) using cetuximab in combination with the FOLFIRI regimen in the first line setting. The CELIM trial 7 , a randomized phase II trial, assessing tumor response to neoadjuvant combination chemotherapy with cetuximab reported response rates of 68% with FOLFOX + cetuximab and 57% with FOLFIRI + cetuximab.
Upon further analysis, evidence emerge that other factors are important in predicting response to EGFR inhibitors. KRAS proto-oncogene encodes a small G-protein which is part of the intracellular Ras/RAF/MAPK cascades. Mutations activating the KRAS oncogene can result in a constitutively active KRAS protein and hence dysregulation of this MAPK based pathway downstream of the EGFR effectors. Lievre et al reported possible lack of response in patients with KRAS mutant tumours in 2 retrospective series 8, 9 . In the 2006 report, the authors noted a response rate of 65% (wild type) versus 0% (mutant) in their cohort of 30 patients with KRAS mutation status analyzed. In their 2008 series, they collected 89 patients with known KRAS mutation status with a response rate of 43% (wild type) versus 0% (mutant). Two other retrospective series also reported similar findings: Di Fiore et al 10 analyzed 59 patients with response rates of 28% (wild type) versus 0% (mutant); De Roock et al 11 looked at 113 patients with response rates of 41% (wild type) versus 0% (mutant).
These observations were further supported by prospective trial data. Analysis of the NCIC CO.17 12 data (best supportive care versus cetuximab) showed improved PFS (1.9 versus 3.7 months; p<0.001) and overall survival (OS) (4.8 versus 9.5 months; p<0.001) with cetuximab in patients with KRAS wild type tumors; but no benefits ( Activating somatic KRAS mutation occurs in about 40% of patients with metastatic colorectal cancer. Taken together, the above data indicates that patients with KRAS mutation do not benefit from treatment with an EGFR inhibiting agent. The prognostic value of KRAS mutation independent of treatment with an EGFR inhibitor remains controversial 18, 19 .
However, despite the identification of KRAS mutation as a marker of non-response to EGFR inhibitors, this accounts for only 30-40% of patients not responsive to treatment. Investigation of further downstream effectors in the RAS-RAF-MAPK pathway reveals BRAF mutation as another potential predictive marker of non-response to EGFR inhibitors. Di Nicolantonio et al 20 performed a retrospective analysis on 113 patients with metastatic colorectal cancer treated with cetuximab or panitumumab. Thirty percent of tumors in this series showed mutant KRAS. Of the 79 out of 113 patients with wild type KRAS, 57 (72%) did not response to EGFR inhibitors treatment. Mutant BRAF V600E was found in 11 out of 79 (14%) of tumors with wild type KRAS. Of these, none responded to EGFR monoclonal antibody treatment. BRAFmutated patients had significantly shorter PFS (p=0.011) and OS (p<0.0001). KRAS and BRAF mutation are also mutually exclusive. The prognostic value of BRAF mutation was investigated in a retrospective series 21 of 168 patients with metastatic colorectal cancer. BRAF was determined to be an independent prognostic factor for decreased PFS (HR 4.0, p<0.001) and overall survival (HR 4.1, p<0.0001). Analysis in stage II and stage III colon cancer patient in a separate study 22 also reported BRAF V600E mutation to be an independent prognostic factor for poorer OS (HR=0.45, 95% CI 0.25-0.8) and cancer specific survival (HR = 0.45, 95% CI 0.38-0.97).
Apart from KRAS and BRAF mutation, other biologic factors under investigation includes amphiregulin, epiregulin, NRAS mutation, PIK3CA pathway activating mutations [23] [24] [25] for prediction of EGFR targeted monoclonal antibodies.
mICrOsAtEllItE INstABIlIty
High frequency microsatellite instability comprises 15 to 20 % of colorectal cancer. Several studies have suggested colorectal cancer patients with defective mismatch repair characterized by high microsatellite instability have better survival than those with low or stable microsatellite instability (MSI-L/S) [26] [27] [28] [29] . A pooled analysis of 7642 patients and reported improved prognosis in patient with VEGF, VEGFR and IL-8 gene polymorphism and expression level.
These markers are currently under investigation for utility in predicting response to VEGF targeted treatment in colorectal cancer.
Thymidylate synthase, Dihydropyrimidinedehydrogenase, ERCC1, UGT1A1 polymorphism.
These markers are being investigated as potential predictor of response to cytotoxic chemotherapy. Thymidylate synthase expression level and Dihydropyrimidine-dehydrogenase activity level as potential marker of response and toxicities to fluorouracil treatment. ERCC1 gene expression level may be useful in predicting response to oxaliplatin. UGT1A1 polymorphism predicts irinotecan related neutropenia. high frequency microsatellite instability treated with adjuvant fluorouracil compared to those with tumors that were microsatellite stable 28 . This is in line with reports from Rubic et al 26 . More recently, Sargent et al 29 reported that patient with defective MMR receiving fluorouracil do not have improvement in DFS compared to those randomly assigned to surgery alone. The data for irinotecan based treatment regimen remains more controversial [30] [31] . The effect of MSI appears greater in Stage II patients on subgroup analysis 31 . Therefore, microsatellite instability may have a role in stratifying Stage II colorectal cancer patient to different treatment strategies.
OthEr BIOmArkErs
Germ-line mutations of APC gene and DNA mismatch repair genes (MSH2, MLH1, PMS1, PMS2, MSH6) can predispose related individuals to developing colorectal cancer. Patients with germ-line mutation of APC have an 80 to 100 percent risk of colorectal cancer and prophylactic protocolectomy or colectomy is recommended at an early age. Germ-line mutations in the DNA mismatch repair genes define hereditary nonpolyposis colon cancer. These patients has a 24 to 75% risk 32 of developing colorectal cancer and require annual colonoscopy beginning at the age of 20 to 25 years and may be considered for prophylactic hysterectomy or colectomy.
Somatic loss of heterozygosity (LOH) of 18q chromosome has been linked to a poor prognosis in colorectal cancer [33] [34] 36 , dihydropyrimidine dehydrogenase to predict fluorouracil response and toxicity [37] [38] , UGT1A1 polymorphism and irinotecan related neutropenia 39 . Biomarkers of response to VEGF targeted treatment under investigation includes VEGF, VEGFR and IL-8 gene polymorphism and expression level [40] [41] [42] [43] .
CONClUsION
The management of colorectal cancers has evolved considerably over the past decade with the availability of more therapeutic drugs and understanding of its molecular pathway of carcinogenesis. With this understanding, comes the realization that not all colorectal cancer patients of a particular stage or clinical characteristics will have the same prognosis or response to a particular chemotherapeutic regimen. The desire to further fine tune this treatment has resulted in a large numbers of putative predictive or prognostic biological markers (Table 1) . However, the way to utilize this plethora of information is far from clear for most markers.
Two targeted therapeutic agents have taken a prominent place in the management of colorectal cancer at this time, namely the EGFR inhibitors and anti-angiogenic VEGF targeted treatment. For the EGFR inhibitors, it has become clear that patients with KRAS mutant tumors would not benefit from these treatments. To date, there is no validated biologic marker that would predict response VEGF targeted anit-angiogenic agents.
The continued search for better selection criteria for patients with stage II or stage III colorectal cancer for adjuvant therapy has lead investigators to look at microsatellite instability and LOH 18q as potential prognosticating and predictive markers. The need to better select and limit the side effect profiles of chemotherapeutic agents has also uncovered various biologic markers (ERCC1, thymidylate synthase, dihydropyrimidine dehydrogenase, UGT1A1) involved in the metabolism or resistance mechanism of cytotoxic chemotherapeutic agents. The place of these markers in the management of colorectal cancer remains to be fully elucidated.
It is apparent that there is heterogeneity amongst colorectal cancers with similar clinical characteristics. Discovering and validating new markers will be important in our quest to provide patients with more personalized care; maximizing benefits while minimizing toxicities. Future directions toward achieving this may include integrative genomic, expression and proteomic arrays research.
